Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
P51178
UPID:
PLCD1_HUMAN
Alternative names:
Phosphoinositide phospholipase C-delta-1; Phospholipase C-III; Phospholipase C-delta-1
Alternative UPACC:
P51178; B3KR14; Q86VN8
Background:
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase delta-1, also known as Phosphoinositide phospholipase C-delta-1, plays a pivotal role in cellular processes by producing second messenger molecules diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3). These molecules are crucial for signal transduction pathways that regulate various cellular functions. The protein binds phosphatidylinositol 4,5-bisphosphate, indicating its central role in phospholipid metabolism.
Therapeutic significance:
The association of 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase delta-1 with non-syndromic congenital nail disorder 3 highlights its clinical relevance. Understanding the role of this protein could open doors to potential therapeutic strategies for treating nail disorders and possibly other related conditions.